Addition of ImmunArray autoimmune testing assets, Nudge patient-engagement capabilities enhances diagnostic and patient support offerings
Addition of ImmunArray autoimmune testing assets, Nudge patient-engagement capabilities enhances diagnostic and patient support offerings
RICHMOND, Va., Aug. 12, 2019 – Salveo Diagnostics, a Richmond, Va.-based advanced laboratory services firm, whose suite of diagnostic tests aims to help reverse the epidemic of chronic disease, has announced the integration of two Richmond-based companies that will broaden the company’s diagnostic capabilities and enhance its service platform.
The integration of ImmunArray, a local molecular diagnostic company that has pioneered technology that includes a blood-based test for the presence of lupus and a development pipeline for other autoimmune diseases, will extend Salveo’s testing capabilities, giving the company new and expanded methods to diagnose diseases by detecting changes in the immune system.
Salveo also recently completed a merger with Nudge, a local behavioral science and technology startup that has developed a health-engagement platform used by coaching, patient engagement and population health initiatives all over the world. The integration of Nudge’s platform and behavior-change methodology will allow patients to access their lab results from their smartphone and proactively manage their health.
“These strategic asset integrations create exponential competencies for Salveo and, by extension, our current and future medical partners,” said Mark Chapman, CEO of Salveo. “We believe that personalized medicine is the only way to reverse the epidemic of chronic disease, and by incorporating the expertise and resources of these two companies, we are even better positioned to support providers and patients alike.”
Terms of the deals were not released.
“The leadership of Salveo and our team recognized the synergy between our current products and their focus on chronic disease and the potential to accelerate the growth of ImmunArray’s proprietary testing platform,” said Donna Edmonds, a board member and former CEO of ImmunArray who now leads ImmunArray spinoff BRAINBox Solutions. “Nearly 50 million Americans are affected by autoimmune diseases, and Salveo now can make a profound and lasting difference in the diagnosis and treatment of these and other diseases.”
“While diagnosis and treatment are major factors in enhancing the health of our nation, so, too, is empowering individuals to make informed decisions about how to improve their personal health,” said Mac Gambill, co-founder and CEO of Nudge. “That is why this strategic integration provides for a more united and effective approach across the expanded capabilities to achieving greater wellness. We are part of a strong foundation and look forward to growing together.”
About Salveo
Founded in 2016, Salveo Diagnostics supports providers and their patients with end-to-end personalized medicine solutions aimed at stopping and reversing the epidemic of chronic disease. The company’s advanced diagnostic testing capabilities span over 400 unique markers and enable targeted, disease-specific testing to help identify root causes from heart disease and stroke, to diabetes, gut dysfunction and inflammation, cognitive decline, autoimmune, and more. Salveo’s testing capabilities are enhanced by a proprietary interpretive commenting algorithm that produces clinically actionable reporting that is personalized based on each patient’s unique test results.
About ImmunArray
Founded in 2006, ImmunArray has developed a series of blood-based tests using its proprietary iCHIP® technology that can determine the presence of a specific set of molecular biomarkers that are linked to particular disease or condition. The company’s first commercially available test is the SLE-Key® Rule-Out Test, to definitively establish that a patient does not have Systemic Lupus Erythematosus (SLE) or lupus. The company has a pipeline of autoimmune tests in development and early work in cancer detection using its technology. It spun out its portfolio of biomarkers in Traumatic Brain Injury into a new company, BRAINBox Solutions, in Q4 of 2018.
About Nudge
Founded in 2013, Nudge is a behavioral science and technology company pioneering solutions for high-touch, remote health coaching and patient engagement. The company’s mobile health engagement platform currently powers hundreds of patient engagement, wellness and population health initiatives all over the world. The platform enables practitioners to craft and deliver tailored health programs and interventions remotely, and gives health consumers easy access to personalized support and tools to sustain engagement.
